At Protheragen, we help out-license and find co-development opportunities for drug development programs. We aspire to play a role in transforming the scientific innovations into medications, helping patients with the most challenging diseases. Our main focus is on oncology programs. Most programs that are available on the list below are at preclinical stage with great therapeutic and market potential.
If you are interested in any of the projects, please contact us for further discussion. We look forward to our collaboration.
| Program | Indication | Discovery | Preclinical | PhaseⅠ | PhaseⅡ | PhaseⅢ |
| Antibody Therapy | ||||||
| Antibody Product Portfolio | Cancer |
|
||||
| ANTIGN-109 | Cancer |
|
||||
| ANTICA-201 | Cancer |
|
||||
| CD3XCD20 bsAb | Lymphomas |
|
||||
| Cl3hmAb | Acquired immune deficiency syndrome |
|
||||
| Anti-MUC1-Ab | Solid tumor |
|
||||
| CD3xBCMA-bsAb | Multiple myeloma |
|
||||
| IGY-110 | Covid-19 |
|
||||
| Anti-LAG3 mAb | Cancer |
|
||||
| OX40-Ab | Cancer |
|
||||
| Recombinant Protein Therapy | ||||||
| P75NEURO | Neurological diseases |
|
||||
| P11 | Type 2 diabetes |
|
||||
| Angiocidin | Acute myeloid leukemia |
|
||||
| TT-173 | Surgical bleeding and trauma |
|
||||
| Oncolytic Virotherapy | ||||||
| RV-scFv-PDL1 | Cancer |
|
||||
| OV-FV-01 | Cancer |
|
||||
| Small Molecules | ||||||
| Polyoxygenated Cyclohexene Compound 4 | Pain |
|
||||
| Fascin Inhibitor | Cancer |
|
||||
| Mitochondrial Uncoupling Agent | Nonalcoholic steatohepatitis |
|
||||
| HBV Capsid Inhibitor | Hepatitis B |
|
||||
| KCNQ2/3 Potassium Channel Opener | Epilepsy |
|
||||
| Resveratrol (Micellar) | Alzheimer’s disease |
|
||||
| Inflammatory factor regulators | Psoriasis |
|
||||
| NMMHC IIA Inhibitors | Thrombosis |
|
||||
| VISTA Agonist | Psoriasis |
|
||||
| Berbamine Analogues | (+)ssRNA virus infections |
|
||||
| Intravenous Anesthetics | Anesthesia |
|
||||
| Water-soluble Taxanes | cancer |
|
||||
| Anti-vimentin Small Molecule | Fibrosis; Viral infection |
|
||||
| Cell Therapy | ||||||
| Double Negative T Cells | Acute myelocytic leukemia |
|
||||
| Anti-BCMA CAR-T Cell | Multiple myeloma |
|
||||
| CD147-CAR-NK | Hepatocellular carcinoma |
|
||||
| RNA Therapy | ||||||
| RNA4TNBC | Triple-negative breast cancer |
|
||||
Protheragen’s business is growing rapidly after founded in Ronkonkoma, New York. More offices have been established at different locations across China and the US ever since.
 |
Protheragen Inc. |
 |
Quick Links |